LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "plus ipilimumab" as a keyword



Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma

Sign Up to like & get
recommendations! Published in 2019 at "JAMA Dermatology"

DOI: 10.1001/jamadermatol.2018.3958

Abstract: Importance A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival (PFS) but noted objective response rates (ORRs) of 38.8%… read more here.

Keywords: talimogene laherparepvec; life; laherparepvec plus; plus ipilimumab ... See more keywords

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis

Sign Up to like & get
recommendations! Published in 2019 at "JAMA Oncology"

DOI: 10.1001/jamaoncol.2018.7086

Abstract: Importance Recently, new drugs have been approved for the first-line treatment of metastatic renal cell carcinoma (mRCC). Nivolumab plus ipilimumab significantly increases overall survival for intermediate- and poor-risk patients with mRCC. However, considering the high… read more here.

Keywords: first line; sunitinib; nivolumab plus; plus ipilimumab ... See more keywords

Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.

Sign Up to like & get
recommendations! Published in 2022 at "JAMA oncology"

DOI: 10.1001/jamaoncol.2022.5409

Abstract: Importance Increased survival with immune checkpoint inhibitors has been reported for patients with obesity vs a normal body mass index (BMI). However, the association of obesity with the safety of immune checkpoint inhibitors warrants study.… read more here.

Keywords: nivolumab plus; patients obesity; plus ipilimumab; grade iraes ... See more keywords

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

Sign Up to like & get
recommendations! Published in 2025 at "Cancer Medicine"

DOI: 10.1002/cam4.70997

Abstract: Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, considering prior ICI… read more here.

Keywords: organ specific; plus ipilimumab; advanced hepatocellular; hepatocellular carcinoma ... See more keywords

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

Sign Up to like & get
recommendations! Published in 2022 at "ESMO Open"

DOI: 10.1016/j.esmoop.2022.100394

Abstract: Background Nivolumab plus ipilimumab demonstrated clinically meaningful improvement in efficacy versus chemotherapy with a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% or read more here.

Keywords: nivolumab plus; chemotherapy; plus ipilimumab; checkmate 227 ... See more keywords
Photo from academic.microsoft.com

Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma.

Sign Up to like & get
recommendations! Published in 2018 at "European urology"

DOI: 10.1016/j.eururo.2018.07.019

Abstract: Expert's summary: Checkmate 214 is a randomised trial comparing the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab (IN) in combination with sunitinib in previously untreated metastatic renal cell carcinoma (mRCC). The results showed significantly better… read more here.

Keywords: cell carcinoma; renal cell; nivolumab plus; plus ipilimumab ... See more keywords
Photo from wikipedia

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Sign Up to like & get
recommendations! Published in 2021 at "The Lancet"

DOI: 10.1016/s0140-6736(20)32714-8

Abstract: BACKGROUND Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including… read more here.

Keywords: chemotherapy; malignant pleural; plus ipilimumab; group ... See more keywords

Nivolumab plus ipilimumab in malignant pleural mesothelioma

Sign Up to like & get
recommendations! Published in 2022 at "Expert Review of Anticancer Therapy"

DOI: 10.1080/14737140.2022.2102482

Abstract: ABSTRACT Introduction Unresectable pleural mesothelioma is a poor prognosis disease. Improvement in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN. BEVACIZUMAB combined with chemotherapy is associated with an improvement in OS, compared… read more here.

Keywords: malignant pleural; pleural mesothelioma; mesothelioma; ipilimumab malignant ... See more keywords

Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.

Sign Up to like & get
recommendations! Published in 2022 at "Japanese journal of clinical oncology"

DOI: 10.1093/jjco/hyac009

Abstract: BACKGROUND Immune checkpoint inhibitors cause various immune-related adverse events. The present study examined the association between the incidence of immune-related adverse events and survival outcomes in patients treated with nivolumab plus ipilimumab for patients with… read more here.

Keywords: immune related; related adverse; nivolumab plus; adverse events ... See more keywords

Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study)

Sign Up to like & get
recommendations! Published in 2022 at "Japanese Journal of Clinical Oncology"

DOI: 10.1093/jjco/hyac124

Abstract: Abstract Background Nivolumab plus ipilimumab combination therapy is one of the standard therapies for untreated renal cell carcinoma patients with an International Metastatic Renal Cell Carcinoma Database Consortium intermediate/poor risk. We have previously reported the… read more here.

Keywords: cell carcinoma; renal cell; therapy; nivolumab plus ... See more keywords

Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up.

Sign Up to like & get
recommendations! Published in 2024 at "Japanese journal of clinical oncology"

DOI: 10.1093/jjco/hyae001

Abstract: BACKGROUND Long-term follow-up data regarding treatment outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma as a first-line therapy are limited in real-world Japanese populations. METHODS We retrospectively evaluated data of 56… read more here.

Keywords: advanced renal; plus ipilimumab; cell; cell carcinoma ... See more keywords